Evidence map›Paper›PMID 37502665›Full record

ArticleMolecular therapy. Methods & clinical development2023

Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine.

Ekramy E Sayedahmed, Marcelo Valdemir Araújo, Taiana Tainá Silva-Pereira, Shubhada K Chothe, Ahmed Elkashif, Marwa Alhashimi, Wen-Chien Wang, Andrea P Santos, Meera Surendran Nair, Abhinay Gontu and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 2 countries.

Ekramy E SayedahmedDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
Marcelo Valdemir AraújoDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Taiana Tainá Silva-PereiraDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Shubhada K ChotheDepartment of Veterinary and Biomedical Sciences, Pennsylvania State University, University Park, PA, USA.
Ahmed ElkashifDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
Marwa AlhashimiDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
Wen-Chien WangDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
Andrea P SantosDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
Meera Surendran NairDepartment of Veterinary and Biomedical Sciences, Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, USA.
Abhinay GontuDepartment of Veterinary and Biomedical Sciences, Pennsylvania State University, University Park, PA, USA.
Ruth NisslyAnimal Diagnostic Laboratory, Department of Veterinary and Biomedical Sciences, Pennsylvania State University, University Park, PA, USA.
Antônio Francisco de Souza FilhoDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Mariana Silva TavaresDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Marina Caçador AyupeDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Caio Loureiro SalgadoDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Érika Donizetti de Oliveira CandidoDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Danielle Bruna Leal OliveiraDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Edison Luiz DurigonDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Marcos Bryan HeinemannDepartment of Preventive Veterinary Medicine and Animal Health, College of Veterinary Medicine, University of São Paulo, São Paulo, Brazil.
Denise Morais da FonsecaDepartment of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Chinnaswamy JagannathDepartment of Pathology and Genomic Medicine, Center for Infectious Diseases and Translational Medicine, Houston Methodist Research Institute, Houston, TX, USA.
Ana Marcia Sá GuimarãesDepartment of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Suresh V KuchipudiAnimal Diagnostic Laboratory, Department of Veterinary and Biomedical Sciences, Pennsylvania State University, University Park, PA, USA.
Suresh K MittalDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA.
Universidade de São Paulo · BRPurdue University West Lafayette · USPennsylvania State University · USHouston Methodist · US

Funding

Novel delivery platform and antigen design for an effective COVID-19 vaccineR01AI158177 · NIAID · PURDUE UNIVERSITY · PI MITTAL, SURESH K · 2020 to 2025
$3.9M
NIAID NIH HHS R01 AI158177
6 · The paper itself

Abstract

Because of continual generation of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is critical to design the next generation of vaccines to combat the threat posed by SARS-CoV-2 variants. We developed human adenovirus (HAd) vector-based vaccines (HAd-Spike/C5 and HAd-Spike) that express the whole Spike (S) protein of SARS-CoV-2 with or without autophagy-inducing peptide C5 (AIP-C5), respectively. Mice or golden Syrian hamsters immunized intranasally (i.n.) with HAd-Spike/C5 induced similar levels of S-specific humoral immune responses and significantly higher levels of S-specific cell-mediated immune (CMI) responses compared with HAd-Spike vaccinated groups. These results indicated that inclusion of AIP-C5 induced enhanced S-specific CMI responses and similar levels of virus-neutralizing titers against SARS-CoV-2 variants. To investigate the protection efficacy, golden Syrian hamsters immunized i.n. either with HAd-Spike/C5 or HAd-Spike were challenged with SARS-CoV-2. The lungs and nasal turbinates were collected 3, 5, 7, and 14 days post challenge. Significant reductions in morbidity, virus titers, and lung histopathological scores were observed in immunized groups compared with the mock- or empty vector-inoculated groups. Overall, slightly better protection was seen in the HAd-Spike/C5 group compared with the HAd-Spike group.

Indexed as

adenovirus vectorautophagyenhanced spike-specific T cell responseGolden Syrian hamstershistopathology scoreintranasal innoculationlung virus titerSARS-CoV-2 vaccineSARS-CoV-2 variantsvaccination

Identifiers

PMID37502665
PMCPMC10299838
OpenAlexW4382196288

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.